NLRP3 and diabetic kidney disease: Tanshinone IIA effectively delays the progression of DKD by regulating the activity of Txnip/NLRP3 inflammatory vesicles, inhibiting the pyroptosis pathway, and protecting microvascular endothelial cells (Wu et al., 2023).